Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-MYC antisense therapeutic
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Anti-MYC antisense therapeutics are a class of RNA-based drugs designed to inhibit the expression of the MYC oncogene, a master regulator of cell growth and metabolism that is frequently overexpressed in human cancers. These agents, such as the novel antisense therapeutic developed at Stanford University, utilize antisense oligonucleotides to bind specifically to MYC mRNA, preventing its translation into protein. Preclinical studies have demonstrated that suppression of MYC can induce sustained tumor regression in models of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) through the reversal of oncogene addiction. Unlike some other MYC-targeting strategies, these antisense approaches have shown the potential for potent anti-tumor activity without significant systemic toxicity in vital organs.
- Other names
- anti-MYC antisense therapeuticMYC antisense oligonucleotideanti-MYC ASO
02
Targets
MYC (MYC proto-oncogene protein)NEAT1 (Nuclear paraspeckle assembly transcript 1)RNASEH1 (Ribonuclease H1)
Beyond the preview
Go deeper on anti-MYC antisense therapeutic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-MYC antisense therapeutic.